Zhang Song, Zhang Dong, Gong Mingfu, Wen Li, Liao Cuiwei, Zou Liguang
Department of Radiology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
BMC Cancer. 2017 May 17;17(1):335. doi: 10.1186/s12885-017-3338-x.
Lymphatic vessel density and lymphovascular invasion are commonly assessed to identify the clinicopathological outcomes in breast cancer. However, the prognostic values of them on patients' survival are still uncertain.
Databases of PubMed, Embase, and Web of Science were searched from inception up to 30 June 2016. The hazard ratio with its 95% confidence interval was used to determine the prognostic effects of lymphatic vessel density and lymphovascular invasion on disease-free survival and overall survival in breast cancer.
Nineteen studies, involving 4215 participants, were included in this study. With the combination of the results of lymphatic vessel density, the pooled hazard ratios and 95% confidence intervals were 2.02 (1.69-2.40) for disease-free survival and 2.88 (2.07-4.01) for overall survival, respectively. For lymphovascular invasion study, the pooled hazard ratios and 95% confidence intervals were 1.81 (1.57-2.08) for disease-free survival and 1.64 (1.43-1.87) for overall survival, respectively. In addition, 29.56% (827/2798) of participants presented with lymphovascular invasion in total.
Our study demonstrates that lymphatic vessel density and lymphovascular invasion can predict poor prognosis in breast cancer. Standardized assessments of lymphatic vessel density and lymphovascular invasion are needed.
通常通过评估淋巴管密度和淋巴管浸润来确定乳腺癌的临床病理结果。然而,它们对患者生存的预后价值仍不确定。
检索了PubMed、Embase和Web of Science数据库,检索时间从建库至2016年6月30日。采用风险比及其95%置信区间来确定淋巴管密度和淋巴管浸润对乳腺癌无病生存期和总生存期的预后影响。
本研究纳入了19项研究,涉及4215名参与者。结合淋巴管密度的结果,无病生存期的合并风险比及95%置信区间分别为2.02(1.69 - 2.40)和总生存期为2.88(2.07 - 4.01)。对于淋巴管浸润研究,无病生存期的合并风险比及95%置信区间分别为1.81(1.57 - 2.08)和总生存期为1.64(1.43 - 1.87)。此外,总共29.56%(827/2798)的参与者出现淋巴管浸润。
我们的研究表明,淋巴管密度和淋巴管浸润可预测乳腺癌的不良预后。需要对淋巴管密度和淋巴管浸润进行标准化评估。